PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Centre for Inflammation Research, Queen\'s Medical Research Institute, The University of Edinburgh, Edinburgh, UK.\', \'Royal Infirmary of Edinburgh, NHS Lothian, Edinburgh, UK.\', \'Regional Infectious Diseases Unit, NHS Lothian, Edinburgh, UK.\', \'Edinburgh Clinical Trials Unit, The University of Edinburgh, Edinburgh, UK.\', \'Centre for Cardiovascular Science, Queen\'s Medical Research Institute, The University of Edinburgh, Edinburgh, UK.\', \'Centre for Inflammation Research, Queen\'s Medical Research Institute, The University of Edinburgh, Edinburgh, UK Kev.Dhaliwal@ed.ac.uk.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1136/bmjopen-2021-054442
?:doi
?:hasPublicationType
?:journal
  • BMJ open
is ?:pmid of
?:pmid
?:pmid
  • 34911721
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.372
?:rankingScore_hIndex
  • 57
?:title
  • Evaluation of new or repurposed treatments for COVID-19: protocol for the phase Ib/IIa DEFINE trial platform.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34911721>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34911721>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all